Mode
Text Size
Log in / Sign up
Phase 2 N=130 Randomized Double-blind Treatment

B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial

Heart Failure · Heart Failure Acute · Acute Cardiac Pulmonary Edema · Acute Cardiac Failure

Enrolled (actual)
130
Serious AEs
3.1%
Results posted
May 2020
Primary outcome: Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
LUS-guided strategy-of-care (Other); Usual Care (Other); Intravenous Loop Diuretic (Drug); Vasodilator (Drug); Non invasive Ventilation (NIV) (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Indiana University
Primary completion
Mar 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management
7; 10

Summary

Nearly 80% of acute heart failure (AHF) patients admitted to the hospital are initially treated in the emergency department (ED). Once admitted, within 30 days post-discharge, 27% of patients are re-hospitalized or die. Attempts to improve outcomes with novel therapies have all failed. The evidence for existing AHF therapies are poor: No currently used AHF treatment is known to improve outcomes. ED treatment is largely the same today as 40 years ago. Congestion, such as difficulty breathing, weight gain, and leg swelling, is the primary reason why patients present to the hospital for AHF. Treating congestion is the cornerstone of AHF management. Yet half of all AHF patients leave the hospital inadequately decongested. The investigators propose a novel approach to aggressively decongest patients in the ED setting: lung ultrasound guided, protocol driven, AHF management. LUS B-lines are a measure of extra-vascular lung water (EVLW). In the setting of AHF, LUS B-lines are a measure of congestion. This simple, easily learned technique has excellent reliability and reproducibility. The investigators hypothesize that a strategy-of-care will outperform usual care. At the present time, usual care is largely empirical. This study will improve the evidence base for ED AHF management. This proposed pilot study, if successful, will lead to an outcome trial examining whether an ED AHF strategy-of-care increases days alive and out of the hospital for patients.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 21 years
  • Presents with shortness of breath at rest or with minimal exertion
  • Clinical diagnosis of AHF and presence of > 15 total bilateral B-lines distributed in at least 4 zones on initial LUS
  • Hx of chronic HF and any one of the following:
  • Chest radiograph consistent with AHF
  • Jugular venous distension
  • Pulmonary rales on auscultation
  • Lower extremity edema

Exclusion Criteria

  • Chronic renal dysfunction, including end-stage renal disease (ESRD) or estimated glomerular filtration rate (eGFR) 175 mmHg
  • Need for immediate intubation
  • Acute Coronary Syndrome- Presentation consistent with myocardial ischemia AND either new ST-segment elevation/depression
  • Fever >101.5 ºF or chest radiograph or clinical picture of pneumonia
  • End stage HF: transplant list, ventricular assist device
  • Anemia requiring transfusion
  • Known interstitial lung disease
  • Suspected acute lung injury or acute respiratory distress syndrome (ARDS)
  • Pregnant or recently pregnant within the last 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03136198). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search